The data highlights significant variance in respiratory system medicine sales across different countries in 2024, measured in US Dollars PPP per capita. Ireland leads with $65.1, followed by the Czech Republic and Norway with $63.1 and $59.8 respectively. Germany and Sweden also have robust figures at $53.4 and $54.5. On the lower end, Japan and Mexico report $8.1 and $4.3.
Year-on-year analysis indicates varying growth rates. Austria shows a notable 10.02% increase, and Germany follows with a 7.1% rise. In contrast, Mexico and Japan have seen declines of 2.58% and 0.96% respectively. Over the last five years, the average growth rate has been moderated by both rising and declining trends across countries.
Future trends to watch include digital health integration and evolving pharmacological advancements, which could drive rapid growth, while economic uncertainties may pose challenges. Monitoring these elements will provide further insight into market dynamics.
Top countries in Respiratory System Medicine Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Ireland | 65.1 | 2023 | +5.34% | +2.2% | View data |
| 2 | 2 Czech Republic | 63.1 | 2023 | +10.51% | +1.7% | View data |
| 3 | 3 Norway | 59.8 | 2023 | +3.82% | +4.15% | View data |
| 4 | 4 Sweden | 54.5 | 2023 | +2.44% | +5.25% | View data |
| 5 | 5 Germany | 53.4 | 2023 | +5.95% | +7.1% | View data |
| 6 | 6 Austria | 44.5 | 2023 | +9.07% | +10.02% | View data |
| 7 | 7 Portugal | 43.7 | 2023 | -8.58% | +2.04% | View data |
| 8 | 8 Estonia | 40.7 | 2023 | -4.91% | +3.79% | View data |
| 9 | 9 Luxembourg | 39.7 | 2023 | +0.51% | +5.98% | View data |
| 10 | 10 Hungary | 23.8 | 2023 | +0.85% | -1.6% | View data |
